NEO vs QURE

NeoGenomics exhibits a stable financial foundation with a Piotroski F-Score of 5/9 and exceptional liquidity (Current Ratio 4.26), though it remains unprofitable with a -14.85% profit margin. While the company has a remarkable track record of beating earnings estimates and shows positive YoY EPS growth, this is offset by a disastrous 5-year price decline of 83.1% and bearish insider activity. The stock appears undervalued relative to analyst targets ($14.81), but the lack of current profitability and negative technical trends suggest a speculative recovery play rather than a value certainty.

The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe financial deterioration. While the company maintains a high current ratio (10.43) providing a short-term liquidity buffer, the operating margin of -900.93% and a Price/Sales ratio of 68.29 suggest an extreme valuation disconnect from fundamental performance. Bearish insider activity from the CEO and CFO, combined with a 0/100 technical trend, outweighs the optimistic analyst target prices. The company remains a high-risk speculative play dependent on future clinical success and additional capital raises.